Steven Lichtman
Stock Analyst at Oppenheimer
(3.14)
# 2,451
Out of 4,874 analysts
66
Total ratings
44.68%
Success rate
14.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $312 → $324 | $309.83 | +4.57% | 6 | May 9, 2025 | |
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $85.04 | +23.47% | 8 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $91.74 | +47.16% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $3.77 | +218.30% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $87.11 | +26.28% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $86.18 | +9.07% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $13.23 | +391.31% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $19.11 | +203.51% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $13.10 | -16.03% | 5 | May 9, 2024 | |
| ANGO AngioDynamics | Upgrades: Outperform | $12 | $9.87 | +21.58% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $92.80 | -6.25% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $58 → $68 | $104.58 | -34.98% | 2 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.65 | +439.29% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $390.40 | -26.23% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $101.06 | +3.90% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $16.81 | +792.33% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $69.69 | +21.97% | 3 | Sep 4, 2020 |
Insulet
May 9, 2025
Maintains: Outperform
Price Target: $312 → $324
Current: $309.83
Upside: +4.57%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $85.04
Upside: +23.47%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $91.74
Upside: +47.16%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $3.77
Upside: +218.30%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $87.11
Upside: +26.28%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $86.18
Upside: +9.07%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $13.23
Upside: +391.31%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $19.11
Upside: +203.51%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $13.10
Upside: -16.03%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $9.87
Upside: +21.58%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $92.80
Upside: -6.25%
Feb 1, 2024
Maintains: Perform
Price Target: $58 → $68
Current: $104.58
Upside: -34.98%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.65
Upside: +439.29%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $390.40
Upside: -26.23%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $101.06
Upside: +3.90%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $16.81
Upside: +792.33%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $69.69
Upside: +21.97%